Eris Lifesciences valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
22.78×————
3.89×————
4.84×————
66.83×————
Enterprise multiples
5.46×————
15.67×————
20.77×————
Yield
4.4%————
1.5%————
Reference — adjusted share basis
₹1,163.60————
₹51.09₹44.73₹25.40₹28.30₹27.59
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ERIS₹1,163.60

Eris Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersMANKINDAJANTPHARMTORNTPHARMEMCUREGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹16,116 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————22.78
P/B————3.89
P/Sales————4.84
Price to Free Cash Flow————66.83
Enterprise Multiples
EV/Sales————5.46
EV/EBITDA————15.67
EV/EBIT————20.77
Yield
Earnings Yield %————4.39
FCF Yield %————1.50
Reference — adjusted share basis
Price (FY-end close, adj.)————1,163.60
EPS (adj.)27.5928.3025.4044.7351.09
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.